GT Biopharma, Inc. (GTBP) vs Longeveron Inc. (LGVN)
A side-by-side comparison of GT Biopharma, Inc. and Longeveron Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GTBP
GT Biopharma, Inc.
$6.32HealthcareDelayed quote: Oct 6, 2026, 1:03 PM EDT
LGVN
Longeveron Inc.
$2.39HealthcareDelayed quote: Oct 6, 2026, 1:05 PM EDT
Total return — GTBP vs LGVN
growth of $100 · dividends reinvested · last 6yGTBP -99.8% (-65.9%/yr)LGVN -99.7% (-61.2%/yr)LGVN compounded faster over this window
GTBP LGVN
GTBP vs LGVN: by the numbers
- •GTBP is the larger company ($8M vs $7M market cap).
- •Both run net losses; GTBP's is the smaller (0.00% vs -1977.59% net margin).
Metrics side by side
Valuation
| Metric | GTBP | LGVN |
|---|---|---|
| P/S ratio | N/A | 6.13 |
| P/B ratio | 2.23 | 0.70 |
Profitability
| Metric | GTBP | LGVN |
|---|---|---|
| Gross margin | 0.00% | 69.76% |
| Operating margin | 0.00% | -1942.20% |
| Net margin | 0.00% | -1977.59% |
| ROE | -618.74% | -225.67% |
| ROIC | -457.75% | -211.58% |
Growth (annualized)
| Metric | GTBP | LGVN |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -21.21% |
| Total return CAGR (5Y) | -73.13% | -62.60% |
Frequently asked
- How have GTBP and LGVN total returns compared?
- Over the past 5 years, GTBP delivered -73.13% and LGVN delivered -62.60% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.